Latest news with #Molteni
The Market Online
2 days ago
- Business
- The Market Online
Cannabis Report: All killer, no filler
Hand holding cannabis extract. (Source: Adobe Stock. Generated by AI) Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, a top Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy. Under the partnership, Tilray Medical subsidiary, FL Group, will provide medical cannabis education throughout Molteni's network of pharmaceutical, scientific and medical professionals in Italy. Click here for the full story. 1 | MediPharm lays out the implications for possible new U.S. cannabis rescheduling 2 | Canopy Growth, Silver North Resources, Vonovia – Clear signals 3 | Aurora Cannabis: Profitability plus falling stock equals value play 4 | Three commodity stocks to strengthen inflation protection Top Cannabis Stocks Aug. 8 to Aug. 14, 2025 1. | 10,556 views | Tilray Brands Inc. 2. | 6,710 views | Medipharm Labs Corp. 3. | 6,665 views | Curaleaf Holdings Inc. 4. | 6,076 views | Canopy Growth Corp. 5. | 1,4750 views | Organigram Holdings Inc. 6. | 911 views | Aurora Cannabis Inc. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here .
The Market Online
3 days ago
- Business
- The Market Online
Tilray expands access to medical cannabis extracts in Italy
Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, an Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy Tilray Brands is a cannabis, beverage, wellness and entertainment company supporting more than 40 brands in more than 20 countries Tilray stock has given back 48.03 per cent year-over-year and 93.28 per cent since May 2021 Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, a top Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy. This content has been prepared as part of a partnership with Tilray Brands Inc., and is intended for informational purposes only. Under the partnership, Tilray Medical subsidiary, FL Group, will provide medical cannabis education throughout Molteni's network of pharmaceutical, scientific and medical professionals in Italy. Founded in 1892 and headquartered in Florence, Molteni maintains operations in more than 40 countries and benefits from in-house manufacturing, research and development, regulatory, supply chain and commercial capabilities, opening the door for future partnerships with Tilray down the line. The new partnership complements Tilray's existing operations in Italy, in addition to presences in Germany, Portugal, Poland and the United Kingdom, with European cannabis revenue growing by 112 per cent in fiscal 2025. Leadership insights 'This partnership reflects our commitment to advancing patient care through strategic collaboration,' Rajnish Ohri, Tilray Brands' Managing Director, International, said in Wednesday's news release. 'By combining FL Group's regulatory and distribution capabilities with Molteni's scientific leadership, we are not only expanding access to high-quality, EU-GMP certified cannabis therapies for patients across Italy but also prioritizing medical cannabis education for pain therapies. Through Molteni's extensive network of healthcare professionals, we aim to empower practitioners with the knowledge and resources needed to support patients seeking effective pain management solutions.' About Tilray Brands Tilray Brands is a cannabis, beverage, wellness and entertainment company supporting more than 40 brands in more than 20 countries. Tilray stock (TSX:TLRY) las traded at C$1.32. The cannabis stock has given back 48.03 per cent year-over-year and 93.28 per cent since May 2021. Join the discussion: Find out what everybody's saying about this Canadian cannabis stock on the Tilray Brands Inc. Bullboard and check out the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
Yahoo
4 days ago
- Business
- Yahoo
Tilray Medical Forms Strategic Partnership in Italy to Broaden Access to Medical Cannabis Extracts
Tilray's FL Group Teams Up with Molteni, a Major Pharmaceutical Firm Focused on Pain and Substance Dependence Therapies NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, announced today that its wholly-owned subsidiary, FL Group S.R.L., has entered into a strategic partnership with L. Molteni & C. dei Alitti Società di Esercizio S.p.A. ('Molteni'), an Italian pharmaceutical firm specializing in pain therapies and substance dependence. The partnership is designed to broaden the availability of Tilray Medical cannabis extracts for patients across Italy. Molteni will collaborate with FL Group by providing targeted education on medical cannabis therapies through Molteni's comprehensive network of pharmaceutical, scientific, and medical professionals throughout Italy. 'This partnership reflects our commitment to advancing patient care through strategic collaboration,' said Rajnish Ohri, Managing Director, International at Tilray Brands. 'By combining FL Group's regulatory and distribution capabilities with Molteni's scientific leadership, we are not only expanding access to high-quality, EU-GMP certified cannabis therapies for patients across Italy but also prioritizing medical cannabis education for pain therapies. Through Molteni's extensive network of healthcare professionals, we aim to empower practitioners with the knowledge and resources needed to support patients seeking effective pain management solutions.' Tilray Medical continues to lead the European medical cannabis market with operations in Germany, Italy, Portugal, Poland, and the United Kingdom. About Tilray Medical Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents. For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand. About Tilray Brands Tilray Brands, Inc. ('Tilray') (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. For more information on how we are elevating lives through moments of connection, visit and follow @Tilray on all social platforms. About Molteni Farmaceutici Molteni Farmaceutici is an Italian pharmaceutical company, a specialty pharma leader in therapeutics solutions for pain management and drug addiction. Founded in 1892 and headquartered in Florence, Italy. With its own Manufacturing, R&D, Regulatory, Supply Chain and Commercial capabilities it is able to serve a broad distribution reach in Europe and across the globe, with operations in over 40 countries. Forward-Looking Statements Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, 'forward-looking statements') under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the 'safe harbor' created by those sections and other applicable laws. Forward-looking statements can be identified by words such as 'forecast,' 'future,' 'should,' 'could,' 'enable,' 'potential,' 'contemplate,' 'believe,' 'anticipate,' 'estimate,' 'plan,' 'expect,' 'intend,' 'may,' 'project,' 'will,' 'would' and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company's ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. For further information: Media: news@ Relations: investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Toronto Star
4 days ago
- Business
- Toronto Star
Tilray Medical Forms Strategic Partnership in Italy to Broaden Access to Medical Cannabis Extracts
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) — Tilray Medical, a division of Tilray Brands, Inc. ('Tilray') (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, announced today that its wholly-owned subsidiary, FL Group S.R.L., has entered into a strategic partnership with L. Molteni & C. dei Alitti Società di Esercizio S.p.A. ('Molteni'), an Italian pharmaceutical firm specializing in pain therapies and substance dependence. The partnership is designed to broaden the availability of Tilray Medical cannabis extracts for patients across Italy. Molteni will collaborate with FL Group by providing targeted education on medical cannabis therapies through Molteni's comprehensive network of pharmaceutical, scientific, and medical professionals throughout Italy.
Daily Record
31-05-2025
- General
- Daily Record
Asparagus will taste like 'restaurant quality' every time if you follow simple two step method
Asparagus can often taste dull and soggy but a top chef has advised how to make the vegetable taste delicious every time and it is very simple two step method. Many of us are guilty of serving soggy asparagus at one point or another but top chef Maurillo Molteni has revealed the best cooking technique to ensure this doesn't happen again. Featuring heavily in spring menus, the head chef at TOZI Victoria has mastered how to lock in all of asparagus' vibrant flavour, colour and crunch and it turns out it's pretty straightforward. Fortunately for us at home, Molteni has shared his fool-proof cooking technique that guarantees delicious restaurant quality results every time. Molteni explains his method step by step, starting with: "If you blanch them, always [do so] in boiling salted water. And as soon as they are cooked (al dente), refresh them in ice water so you keep the colour, texture and flavour." This method not only maintains the vegetable's fresh green hue but also prevents the cooking process instantly to stop any mushiness from happening. According to the cooking guru, the ice bath is an essential final step that many home cooks skip, but it makes all the difference to the finished result, the Express reports. It is the same method used in professional kitchens to keep the ingredients firm and bursting with flavour. Asparagus is a popular ingredient in many of TOZI's most popular seasonal dishes and Molteni is very passionate about letting the vegetable shine. He explained: "Asparagus is very versatile and can be used in different dishes or even served by themselves." At the London-based Italian eatery, guests can enjoy asparagus in a multitude of ways, whether it's paired with quail eggs and black truffle in a salad, folded into rustichella pasta with peas and pecorino, or served simply with brown butter and parmesan. The chef added: "One of TOZI's favourites is the hand-cut tagliarini with asparagus and black truffle—simple but so tasty." Molteni is also a big advocate of reducing food waste, suggesting a clever use for often discarded woody ends of the vegetable. He explained: "With the asparagus ends, I usually do a stock that we use as a base to make asparagus soup, to cook an asparagus risotto and even some pasta dishes." For anyone cooking asparagus at home, Molteni advises peeling the thicker spears halfway down to help them cook evenly and stay tender. His final golden tip is to "just make sure you do not play with them too much — don't overcook them, otherwise you will lose texture and flavour." Asparagus provides a range of health benefits as a good source of fibre, folate, and various vitamins and minerals. It can also support digestion, potentially balance cholesterol, and help maintain healthy blood pressure and bone health.
